Rubric Capital Management LP, an institutional investor, has significantly increased its holdings in Stratasys Ltd. (NASDAQ:SSYS). According to a recent SEC filing, Rubric Capital Management LP has acquired 3,339,367 shares of Stratasys, representing a 366.7% increase in its holdings. The institutional investor now owns a total of 4,250,000 shares of the technology company's stock, making it the 13th largest position in its portfolio. Other large investors have also made changes to their holdings of Stratasys. The company reported earnings per share of $0.02 for the quarter, with revenue totaling $156.34 million. Research analysts have provided their insights on SSYS, with Cantor Fitzgerald reiterating an 'overweight' rating and Needham & Company LLC adjusting their target price on the stock [58d86860].
In addition to its increased holdings in Stratasys, Rubric Capital Management LP has also acquired 2,862,729 shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT). This acquisition brings Rubric Capital Management LP's ownership in the company to 1.98% of the total stock, valued at approximately $14,027,000 [81f9b372].
Cathie Wood's ARK ETFs have made notable moves in its holdings, adjusting its positions in various companies. On May 29, 2024, ARK purchased shares of UIPATH INC, NATERA INC, ADVANCED MICRO DEVICES INC (AMD), and ROBLOX CORP. These purchases indicate ARK's confidence in these companies and their growth prospects. Additionally, ARK sold shares of UNITY SOFTWARE INC and MODERNA INC, possibly adjusting their positions in these companies. ARK also made smaller trades in other companies. These trades reflect ARK's latest convictions in the market [23b24e3b].
Cathie Wood's ARK ETFs have made several notable trades on Tuesday, May 7, 2024. ARK purchased 1,353,667 shares of Palantir Technologies Inc across its ARKK, ARKQ, ARKW, ARKF, and ARKX ETFs, amounting to $34,125,943. ARK also acquired 28,163 shares of Datadog Inc for $3,575,856. On the sell side, ARK divested 70,616 shares of Coinbase Inc, valued at $16,024,888, and 121,367 shares of DraftKings Inc, totaling $5,348,643. Other trades included selling shares of AeroVironment Inc, 2U Inc, and Twist Bioscience Corp. ARK also bought 130,375 shares of Rocket Lab USA Inc for $529,322. ARK's recent trading patterns show a consistent sell-off of 2U Inc and repeated buying of Tesla Inc shares. These trades provide insights into ARK's outlook on various sectors and companies [568fc942].
Cathie Wood's ARK Invest ETFs have published their daily trades for Friday, May 24th, 2024. ARK increased its stake in PayPal Holdings Inc, purchasing 54,210 shares. ARK made a substantial sell-off of Teladoc Health Inc stock, parting with 399,982 shares. ARK also purchased 44,730 shares of Adaptive Biotechnologies Corp. ARK sold a small position of 98 shares in ARK 21Shares Active Strategy ETF. These trades indicate strategic shifts in ARK's portfolio and suggest growing confidence in PayPal and reduced exposure to Teladoc. ARK's active management style is evident in significant moves in the healthcare and technology sectors [5ba97197].
Cathie Wood's Ark Investment Management has increased its equity ownership in gene editing biotechs CRISPR Therapeutics, Intellia Therapeutics, and AI-focused drug discovery firm Recursion Pharmaceuticals. As a result, the shares of these companies have seen a boost. On Tuesday, ARK Innovation ETF and ARK Genomic Revolution purchased nearly 280,000 shares of CRISPR, worth approximately $20 million. Additionally, ARKK and ARKG added over 98,000 shares of Intellia for around $2.6 million and almost 519,000 shares of Recursion for about $5.1 million. These transactions have raised ARK's ownership in each company to approximately 11%. Other notable purchases made by ARK on Tuesday include gene editing biotechs Beam Therapeutics and Verve Therapeutics, as well as life sciences company 10x Genomics [a6765e99].
Joseph E. Turk Jr., a director of ReWalk Robotics Ltd. (NASDAQ:RWLK), has purchased $40,079 worth of ordinary shares in the company. The purchases, made on May 22 and May 23, 2024, involved the acquisition of 84 shares and 7,916 shares, respectively, at a price of $5.01 per share. These transactions indicate Turk's confidence in the company's future and its growth prospects in the field of orthopedic and prosthetic appliances. ReWalk Robotics has been a company of interest for investors in the medical technology sector. The reported shares have been adjusted to reflect the impact of a 1-for-7 reverse share split. Investors will likely monitor insider activity for further indications of the company's trajectory.